Pablo Legorreta, Royalty Pharma CEO (Patrick T. Fallon/Bloomberg via Getty Images)

April 1, 2021 10:55 AM EDT

GlaxoSmithKline offloads royalty rights for 2 cancer drugs in $342M windfall it will use to finance consumer spinoff

Max Gelman

Senior Editor

As GlaxoSmithKline continues plans to spin off its Pfizer-partnered consumer health division, the British pharma pulled in a new heaping of cash to accomplish that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GlaxoSmithKline offloads royalty rights for 2 cancer drugs in $342M windfall it will use to finance consumer spinoff

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Biohaven's myostatin inhibitor misses primary endpoint in spinal muscular atrophy trial

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Gilead buys experimental HIV vaccines from a small Barcelona biotech

Glax­o­SmithK­line of­floads roy­al­ty rights for 2 can­cer drugs in $342M wind­fall it will use to fi­nance con­sumer spin­off

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

Bio­haven's myo­statin in­hibitor miss­es pri­ma­ry end­point in spinal mus­cu­lar at­ro­phy tri­al

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

GlaxoSmithKline offloads royalty rights for 2 cancer drugs in $342M windfall it will use to finance consumer spinoff

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Biohaven's myostatin inhibitor misses primary endpoint in spinal muscular atrophy trial

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Gilead buys experimental HIV vaccines from a small Barcelona biotech